PDCD1 and hepatocellular carcinoma: In addition, it had been reported that the incidence of HBV reactivation in HCC patients undergoing TKIs (lenvatinib, sorafenib, etc.)combined with PD-1 inhibitors (sintilimab, camrelizumab, etc.)therapy is higher than that in patients with TKIs monotherapy (Lei et al., 2023).